Table 3

Seroprevalence at phase II by SARS-CoV-2 infection and vaccination status

PositiveNegativeTotalEstimated seroprevalence in general population
N%N%%95% CIP value
SARS-CoV-2− and no vaccination72825.56212074.44284823.9722.18% to 25.85%
SARS-CoV-2+ and no vaccination436791.004329.00479989.5788.33% to 90.70%
SARS-CoV-2− and with vaccination728597.202102.80749597.3696.72% to 97.88%<0.001
SARS-CoV-2+ and with vaccination696999.73190.27698899.8199.68% to 99.89%
Total19 34987.43278112.5722 13084.3783.64% to 85.07%
  • SARS-CoV-2−=seronegative at phase I AND self-report of negative or not done PCR test between phase I and II.

  • SARS-CoV-2+=seropositive at phase I OR self-report of positive PCR test between phase I and II.